Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
Intradermal delivery of vaccines has been shown to result in dose sparing. We tested the ability of fractional doses of inactivated poliovirus vaccine (IPV) delivered intradermally to induce levels of serum poliovirus-neutralizing antibodies similar to immunization through the intramuscular route. Immunogenicity of fractional doses of IPV was studied by comparing intramuscular and intradermal immunization of Wistar rats using NanoPass MicronJet600 microneedles. Intradermal delivery of partial vaccine doses induced antibodies at titers comparable to those after immunization with full human dose delivered intramuscularly. The results suggest that intradermal delivery of IPV may lead to dose-sparing effect and reduction of the vaccination cost.
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
Diana
D
Kouiavskaia
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
Olga
O
Mirochnitchenko
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
Eugenia
E
Dragunsky
NanoPass Technologies, Nes Ziona, Israel.
Efrat
E
Kochba
NanoPass Technologies, Nes Ziona, Israel.
Yotam
Y
Levin
Eastern Virginia Medical School, Norfolk.
Stephanie
S
Troy
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland.
Konstantin
K
Chumakov
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007271:Injections, Intradermal / Q000295:instrumentation; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D051381:Rats; D017208:Rats, Wistar
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated
dose sparing; immunogenicity; inactivated poliovirus vaccine; intradermal